4 Firms Advise On Genmab's $8B Merus Acquisition Plan

By Al Barbarino ( September 29, 2025, 2:23 PM EDT) -- Genmab AS announced Monday it has agreed to purchase Dutch clinical-stage biotechnology firm Merus NV in an all-cash transaction valued at about $8 billion, with Allen Overy Shearman Sterling and Kromann Reumert advising Genmab and Latham & Watkins LLP and NautaDutilh representing Merus. ...

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login